Brainstorm Cell Therapeutics (BCLI) News Today $1.20 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.20 +0.00 (+0.08%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BCLI Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Brainstorm Cell Therapeutics Inc. BCLI (U.S.: Nasdaq) - The Wall Street ...July 16 at 6:35 AM | wsj.comBrainStorm Cell Therapeutics Inc.: FDA Review of Citizen Petition Offers a Fresh Look at NurOwn's Evidence of Treatment EffectivenessJuly 8, 2025 | finanznachrichten.deFDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment EffectivenessJuly 8, 2025 | prnewswire.comBrainstorm Cell Therapeutics Inc. (BCLI) - Yahoo FinanceJune 29, 2025 | uk.finance.yahoo.comBrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn®June 16, 2025 | prnewswire.comBCLI: Receives Regulatory Clearance to Initiate Phase 3b ALS Trial…May 27, 2025 | finance.yahoo.comBrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical TrialsMay 27, 2025 | prnewswire.comBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q1 2025 Earnings Call TranscriptMay 21, 2025 | msn.comBrainStorm Cell Therapeutics Inc.: BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn for ALSMay 19, 2025 | finanznachrichten.deMicro Cap Bid Up Aggressively On FDA Clearance AnnouncementMay 19, 2025 | msn.comBrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALSMay 19, 2025 | prnewswire.comBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 16, 2025 | finanznachrichten.deBrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | tmcnet.comBrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | prnewswire.comBrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19May 15, 2025 | prnewswire.comBrainStorm Cell Therapeutics Q1 2025 Earnings PreviewMay 14, 2025 | msn.comBrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025May 7, 2025 | prnewswire.comBrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development SummitMay 6, 2025 | prnewswire.comBrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 MeetingApril 29, 2025 | prnewswire.comBrainstorm Cell Therapeutics adjusts quorum requirementApril 23, 2025 | investing.comBrainStorm submits IND amendment to FDA for Phase 3b trial of NurOwn in ALSApril 10, 2025 | markets.businessinsider.comBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn in ALSApril 10, 2025 | finanznachrichten.deBrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALSApril 10, 2025 | prnewswire.comAnalysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Brainstorm Cell Therapeutics (BCLI)April 10, 2025 | markets.businessinsider.comEarnings call transcript: Brainstorm Cell Therapeutics Q4 2024 highlights cost-cuttingApril 2, 2025 | uk.investing.comBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate UpdateApril 1, 2025 | finanznachrichten.deQ4 2024 Brainstorm Cell Therapeutics Inc Earnings CallApril 1, 2025 | finance.yahoo.comBrainstorm Cell Therapeutics Inc. (BCLI) Q4 2024 Earnings Call TranscriptMarch 31, 2025 | seekingalpha.comBrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate UpdateMarch 31, 2025 | prnewswire.comA Preview Of Brainstorm Cell's EarningsMarch 29, 2025 | benzinga.comBrainStorm granted compliance extension from NasdaqMarch 27, 2025 | markets.businessinsider.comBrainStorm Cell Therapeutics Granted Compliance Extension from NasdaqMarch 26, 2025 | prnewswire.comBrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate UpdateMarch 24, 2025 | prnewswire.comBrainstorm Cell Therapeutics Appeals Nasdaq DelistingJanuary 21, 2025 | msn.comBCLI: Plans Coming Together for Phase 3b Trial of NurOwn® in ALS…January 6, 2025 | finance.yahoo.comBrainStorm Issues 2024 Letter to ShareholdersDecember 30, 2024 | prnewswire.comBrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate UpdateDecember 9, 2024 | prnewswire.comBrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform TechnologyDecember 3, 2024 | prnewswire.comBrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024December 2, 2024 | prnewswire.comBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 16, 2024 | finanznachrichten.deBrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 14, 2024 | prnewswire.comBrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial ManufacturingNovember 11, 2024 | prnewswire.comBrainStorm regains compliance with NasdaqOctober 31, 2024 | markets.businessinsider.comBrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementOctober 30, 2024 | prnewswire.comBrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS MeetingOctober 28, 2024 | prnewswire.comBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest UpdateOctober 27, 2024 | marketbeat.comBrainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Cross Above 200-Day Moving Average - Should You Sell?October 18, 2024 | marketbeat.comBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Sees Large Decline in Short InterestOctober 10, 2024 | marketbeat.comBrainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Cross Above 200 Day Moving Average - What's Next?October 9, 2024 | marketbeat.com Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Email Address BCLI Media Mentions By Week BCLI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCLI News Sentiment▼0.840.97▲Average Medical News Sentiment BCLI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCLI Articles This Week▼21▲BCLI Articles Average Week Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AADI News Today PRLD News Today GRCE News Today XCUR News Today SCLX News Today MURA News Today OSTX News Today LTRN News Today MRSN News Today MDCX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCLI) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCLI Stock Alerts